Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,406 across all filing types
Latest filing 2024-07-23 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2024-07-23 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Informations relatives au nombre total de droits de vote et d'actions' (Information relating to the total number of voting rights and shares) and explicitly references French regulations (Article L. 233-8 II du Code de commerce and Article 223-16 du Règlement général de l'Autorité des Marchés Financiers). It provides a table detailing the number of shares and voting rights as of June 30, 2024. This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement, often related to capital structure or shareholder information, but it does not fit perfectly into the defined categories like 10-K, ER, or DIV. It is a specific regulatory update concerning share capital and voting rights. Given the options, 'Share Issue/Capital Change' (SHA) is the closest fit as it deals directly with the capital structure components (total shares and voting rights). It is a direct disclosure of capital structure data, not just an announcement of a report (RPA/RNS).
2024-07-22 French
Sanofi: Information concerning the total number of voting rights and shares – June 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns the 'total number of voting rights and shares' pursuant to French Commercial Code and AMF regulations. It provides a table detailing the 'Total number of issued shares' and 'Number of real voting rights' as of a specific date (June 30, 2024). This type of mandatory disclosure regarding the capital structure and voting power is a specific regulatory filing, but it does not fit perfectly into the provided definitions for 10-K, IR, or ER. It is a notification about the composition of the share capital and voting rights. While it relates to capital structure, it is not a financing announcement (CAP) or a general share issue (SHA). It is a specific regulatory disclosure regarding ownership structure/rights. Given the options, this type of mandatory disclosure about the total number of shares and voting rights, often published monthly or semi-annually in European jurisdictions, is best categorized as a specific regulatory filing that doesn't fit the other detailed categories. It is most closely related to general capital structure information, but since it is a specific regulatory notice about voting rights, and not a general announcement of a dividend (DIV) or a major shareholding change (MRQ), the most appropriate fallback is the general Regulatory Filings category (RNS), as it is a mandatory disclosure under specific local regulations.
2024-07-22 English
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
Earnings Release Classification · 95% confidence The document is explicitly titled "Press Release" and announces the publication of Phase 3 clinical trial data for a drug (ALTUVIIIO XTEND-Kids) in *The New England Journal of Medicine* (*NEJM*). It contains key financial/operational highlights (efficacy, safety, dosing), quotes from management/medical directors, and standard boilerplate sections about the companies (Sanofi, Sobi) and forward-looking statements. This structure is characteristic of an Earnings Release (ER) or a general announcement of significant news. Since it focuses on the release of study results and is formatted as a press release, it aligns best with the 'Earnings Release' definition, which covers initial announcements of periodical results or significant operational milestones, even if not strictly quarterly earnings. It is not a full report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV. Given the context of announcing major clinical data, ER is the most appropriate fit among the provided options. Q3 2024
2024-07-17 English
Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d’hémophi
Earnings Release Classification · 92% confidence The document is a press release dated July 17, 2024, announcing the publication of Phase III study results (XTEND-Kids) for the drug ALTUVIIIO in The New England Journal of Medicine (NEJM). It details efficacy, safety, and pharmacokinetics, and includes quotes from medical experts and company executives. This format—a formal announcement of clinical trial results and their implications, often released concurrently with or immediately following publication in a medical journal—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/product news. Since it focuses on the release of new data/results rather than a comprehensive financial overview (10-K/IR) or a management discussion (MDA), and it is a direct announcement of results, 'ER' (Earnings Release) is the closest fit among the options for a major, time-sensitive corporate announcement, even though it's not strictly quarterly earnings. Given the options, it functions as a major corporate news announcement regarding product data, which often overlaps with the function of an ER in terms of immediacy and importance, or it could be classified as a Regulatory Filing (RNS) if it were a mandatory filing. However, the content is a detailed press release about clinical data publication, making it analogous to an Earnings Release announcing key performance indicators (in this case, clinical performance). Since it is a full press release and not just a short notice of publication, it is not RPA. ER is the best fit for a major, time-sensitive announcement of key operational/product results. Q3 2024
2024-07-17 French
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# **Press Release**' and details the European Medicines Agency (EMA) approval of Dupixent for COPD. It includes key financial/product highlights, quotes from CEOs, and detailed clinical trial results (BOREAS and NOTUS). This format—a formal announcement of a significant event (regulatory approval and associated clinical data) released to the public and media—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific shareholder document (like DEF 14A or DVA), and it serves as the initial public disclosure of this major news, it best fits the 'Earnings Release' category, which often covers major operational or regulatory milestones that impact financial outlook, even if it's not strictly quarterly earnings. Given the options, ER is the closest fit for a major press release announcing a significant product milestone/approval.
2024-07-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.